First-line monochemotherapy with mitoxantrone versus combination with fluorouracil, epirubicin and cyclophosphamide in high-risk metastatic breast cancer: A prospective randomized multicenter clinical trial

Onkologie

Volumn 23, Issue 1, 2000, Pages 54-59

  Heidemann, E ^a   Souchon, R ^b   Stoger H ^b   Hirschmann, W D ^b   Bodenstein, H ^b   Oberhoff, C ^b   Fischer, J T ^b   Schulze, M ^b   Clemens, M ^b   Mahlke, M ^b   Konig M ^b   Scharl, A ^b   Fehnle, K ^b   Kaufmann, M ^b  

^a Onkologischer Schwerpunkt Stuttgart   (Germany)

^b NONE

Author keywords

Breast cancer; Epirubicin; Mitoxantrone; Quality of life; Single agent treatment

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; MITOXANTRONE;

ARTICLE; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 0034012995     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000027078     Document Type: Article

References (19)

1. Heidemann E, Steinke B, Hartlapp J, Schumacher K, Possinger K, Kunz S, Neeser E, v. Ingersleben G, Hossfeld D, Caffier H, Souchon R, Waldmann R, Blümner E, Clark J: Prognostic subgroups: The key factor for treatment outcome in metastatic breast cancer. Onkologie 1993;16:344-353.
2. Heidemann E, Kaesberger J, Herschbach P, Sellschopp A: Graduated WHO analogue and satisfaction scales for the assessment of quality of life in clinical trials in cancer patients. Onkologie 1991;14:419-426.
3. Brunner KW: Evaluation criteria in comparative clinical trials in advanced breast cancer: A proposal for improvement; in Cavalli F (ed): Endocrine Treatment of Breast Cancer II: Current Developments and New Methodologies. European School of Oncology Monograph Series. Berlin, Springer, 1987, pp 47-51.
4. Heidemann E, Steinke B, Hartlapp J, Schumacher K, Possinger K, Kunz S, Neeser E, v. Ingersleben G, Hossfeld D, Caffier H, Souchon R, Waldmann R, Blümner E, Clark J, Schrüffer R: Metastasiertes Mammakarzinom. Prognostische Faktoren bestimmen den Verlauf stärker als die Wahl des Therapieschemas. Akt Onkol 1992;66:71-80.
5. Rahman ZU, Frye DK, Smith TL, Asmar L, Theriault RL, Buzdar A,U Hortobagyi GN: Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy. Cancer 1999;85: 104-111.
6. Ayash LJ, Wheeler C, Fairclough D, Schwartz G, Reich E, Warren D, Schnipper L, Antmann K, Frei E III, Elias A: Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol 1995;13:2043-2049.
7. Smalley RV, Murphy S, Hugley CM, Bartolucci AA: Combination versus sequential five drug chemotherapy in metastatic carcinoma of the breast. Cancer Res 1976;36:3911.
8. Hoogstraten B, George SL, Samal B: Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study. Cancer 1976;38:13-20.
9. Rubens RD, Knight RK, Hayward JL: Chemotherapy of advanced breast cancer: A controlled randomized trial of cyclophosphamide versus a four-drug combination. Br J Cancer 1975;32:730-736.
10. Ahmann DL, Schaid DJ, Bisel HF: The effect on survival of initial chemotherapy in advanced breast cancer: Polychemotherapy versus single drug. J Clin Oncol 1987;5:1928-1932.
11. Carmo-Pereira J, Costa FO, Henriques E: Single-drug vs combination cytotoxic chemotherapy in advanced breast cancer: A randomized study. Eur J Cancer 1980;16:1621-1625.
12. Canellos GP, Pocock SJ, Taylor SG III, Sears ME, Klaasen DJ, Band PR: Combination chemotherapy for metastatic breast carcinoma. Cancer 1976;38:1882-1886.
13. Mouridsen HT, Palshof T, Brahm M: Evaluation of single-drug versus multiple-drug chemotherapy in the treatment of advanced breast cancer. Cancer Treat Rep 1971;61:47-50.
14. Chlebowski RT, Irwin LE, Pugh RP: Survival of patients with metastatic breast cancer treated with either combination or sequential chemotherapy. A Western Cancer Study Group Project. Cancer Res 1979;39:4503.
15. Chlebowski RT, Smalley RV, Weiner JM, Irwin LE, Bartolucci AA, Bateman JR: Combination versus sequential single agent chemotherapy in advanced breast cancer: Associations with metastatic sites and long-term survival. The Western Cancer Study Group and The Southeastern Cancer Study Group. Br J Cancer 1989;59:227-230.
16. Joensuu H, Holli K, Heikkinen M, Suonio E, Aro AR, Hietanen P, Huovinen R: Combination chemotherapy versus single-agent therapy as first-and second-line treatment in metastatic breast cancer: A prospective randomized trial. J Clin Oncol 1998;16:3720-2730.
17. Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, Tinazzi A, Liberati A: Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31,510 women. J Clin Oncol 1998;10:3439-3460.
18. French Epirubicin Study Group: A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. J Clin Oncol 1991;9:305-312.
19. Habeshaw T, Paul J, Jones R, Stallard S, Stewart M, Kaye SB, Soukop M, Symonds RP Reed NS, Rankin EM: Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: The results of a randomized trial. J Clin Oncol 1991;9:295-304.